Defining nonvalvular atrial fibrillation: A quest for clarification
Non–vitamin K oral anticoagulants (NOACs) are currently recommended for patients with nonvalvular atrial fibrillation since the publication of the 4 major pivotal trials evaluating the efficacy and safety of factor IIa and factor Xa inhibitors. The definition of nonvalvular atrial fibrillation is un...
Saved in:
Published in | The American heart journal Vol. 178; pp. 161 - 167 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.08.2016
Elsevier Limited Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Non–vitamin K oral anticoagulants (NOACs) are currently recommended for patients with nonvalvular atrial fibrillation since the publication of the 4 major pivotal trials evaluating the efficacy and safety of factor IIa and factor Xa inhibitors. The definition of nonvalvular atrial fibrillation is unclear, varying from one trial to another and even between North American and European guidelines, which is a source of uncertainties in clinical practice. However, many patients with atrial fibrillation present signs of valvular involvement, and clarification of this term is needed to not deny NOACs to patients based on the wrong perception that they may have valvular atrial fibrillation.
The currently unique contraindications to NOACs are patients with mechanical heart valves and those with moderate-to-severe mitral stenosis, as stated by the recent 2015 position paper of the European Heart Rhythm Association. Patients with native heart valve involvement, regardless of their severity, are suitable for NOAC therapy. Patients with bioprosthetic heart valves and mitral valve repair may be suitable for NOACs except for the first 3 and the first 3-6 months postoperatively, respectively. Patients with transaortic valve implantation or percutaneous transluminal aortic valvuloplasty are also considered as being eligible for NOACs, although the bleeding risk has to be carefully considered in this population often requiring a combination with antiplatelet therapy.
Future studies are warranted to increase the level of evidence of use of NOACs, particularly in patients with transaortic valve implantation and valvular surgery, and to determine whether they could be used in the future in the only 2 remaining contraindications. |
---|---|
AbstractList | Non-vitamin K oral anticoagulants (NOACs) are currently recommended for patients with nonvalvular atrial fibrillation since the publication of the 4 major pivotal trials evaluating the efficacy and safety of factor IIa and factor Xa inhibitors. The definition of nonvalvular atrial fibrillation is unclear, varying from one trial to another and even between North American and European guidelines, which is a source of uncertainties in clinical practice. However, many patients with atrial fibrillation present signs of valvular involvement, and clarification of this term is needed to not deny NOACs to patients based on the wrong perception that they may have valvular atrial fibrillation. The currently unique contraindications to NOACs are patients with mechanical heart valves and those with moderate-to-severe mitral stenosis, as stated by the recent 2015 position paper of the European Heart Rhythm Association. Patients with native heart valve involvement, regardless of their severity, are suitable for NOAC therapy. Patients with bioprosthetic heart valves and mitral valve repair may be suitable for NOACs except for the first 3 and the first 3-6 months postoperatively, respectively. Patients with transaortic valve implantation or percutaneous transluminal aortic valvuloplasty are also considered as being eligible for NOACs, although the bleeding risk has to be carefully considered in this population often requiring a combination with antiplatelet therapy. Future studies are warranted to increase the level of evidence of use of NOACs, particularly in patients with transaortic valve implantation and valvular surgery, and to determine whether they could be used in the future in the only 2 remaining contraindications. Non-vitamin K oral anticoagulants (NOACs) are currently recommended for patients with nonvalvular atrial fibrillation since the publication of the 4 major pivotal trials evaluating the efficacy and safety of factor IIa and factor Xa inhibitors. The definition of nonvalvular atrial fibrillation is unclear, varying from one trial to another and even between North American and European guidelines, which is a source of uncertainties in clinical practice. However, many patients with atrial fibrillation present signs of valvular involvement, and clarification of this term is needed to not deny NOACs to patients based on the wrong perception that they may have valvular atrial fibrillation. The currently unique contraindications to NOACs are patients with mechanical heart valves and those with moderate-to-severe mitral stenosis, as stated by the recent 2015 position paper of the European Heart Rhythm Association. Patients with native heart valve involvement, regardless of their severity, are suitable for NOAC therapy. Patients with bioprosthetic heart valves and mitral valve repair may be suitable for NOACs except for the first 3 and the first 3-6 months postoperatively, respectively. Patients with transaortic valve implantation or percutaneous transluminal aortic valvuloplasty are also considered as being eligible for NOACs, although the bleeding risk has to be carefully considered in this population often requiring a combination with antiplatelet therapy. Future studies are warranted to increase the level of evidence of use of NOACs, particularly in patients with transaortic valve implantation and valvular surgery, and to determine whether they could be used in the future in the only 2 remaining contraindications. © 2016 Elsevier, Inc. Non–vitamin K oral anticoagulants (NOACs) are currently recommended for patients with nonvalvular atrial fibrillation since the publication of the 4 major pivotal trials evaluating the efficacy and safety of factor IIa and factor Xa inhibitors. The definition of nonvalvular atrial fibrillation is unclear, varying from one trial to another and even between North American and European guidelines, which is a source of uncertainties in clinical practice. However, many patients with atrial fibrillation present signs of valvular involvement, and clarification of this term is needed to not deny NOACs to patients based on the wrong perception that they may have valvular atrial fibrillation. The currently unique contraindications to NOACs are patients with mechanical heart valves and those with moderate-to-severe mitral stenosis, as stated by the recent 2015 position paper of the European Heart Rhythm Association. Patients with native heart valve involvement, regardless of their severity, are suitable for NOAC therapy. Patients with bioprosthetic heart valves and mitral valve repair may be suitable for NOACs except for the first 3 and the first 3-6 months postoperatively, respectively. Patients with transaortic valve implantation or percutaneous transluminal aortic valvuloplasty are also considered as being eligible for NOACs, although the bleeding risk has to be carefully considered in this population often requiring a combination with antiplatelet therapy. Future studies are warranted to increase the level of evidence of use of NOACs, particularly in patients with transaortic valve implantation and valvular surgery, and to determine whether they could be used in the future in the only 2 remaining contraindications. Non-vitamin K oral anticoagulants (NOACs) are currently recommended for patients with nonvalvular atrial fibrillation since the publication of the 4 major pivotal trials evaluating the efficacy and safety of factor IIa and factor Xa inhibitors. The definition ofnonvalvular atrial fibrillationis unclear, varying from one trial to another and even between North American and European guidelines, which is a source of uncertainties in clinical practice. However, many patients with atrial fibrillation present signs of valvular involvement, and clarification of this term is needed to not deny NOACs to patients based on the wrong perception that they may have valvular atrial fibrillation. The currently unique contraindications to NOACs are patients with mechanical heart valves and those with moderate-to-severe mitral stenosis, as stated by the recent 2015 position paper of the European Heart Rhythm Association. Patients with native heart valve involvement, regardless of their severity, are suitable for NOAC therapy. Patients with bioprosthetic heart valves and mitral valve repair may be suitable for NOACs except for the first 3 and the first 3-6 months postoperatively, respectively. Patients with transaortic valve implantation or percutaneous transluminal aortic valvuloplasty are also considered as being eligible for NOACs, although the bleeding risk has to be carefully considered in this population often requiring a combination with antiplatelet therapy. Future studies are warranted to increase the level of evidence of use of NOACs, particularly in patients with transaortic valve implantation and valvular surgery, and to determine whether they could be used in the future in the only 2 remaining contraindications. |
Author | Colette, Edouard Galand, Vincent Mabo, Philippe Pavin, Dominique Daubert, Jean-Claude Behar, Nathalie Leclercq, Christophe Martins, Raphaël P. |
Author_xml | – sequence: 1 givenname: Raphaël P. surname: Martins fullname: Martins, Raphaël P. email: raphael.martins@chu-rennes.fr organization: CHU Rennes, Service de Cardiologie et Maladies Vasculaires, Rennes, F-35000, France – sequence: 2 givenname: Vincent surname: Galand fullname: Galand, Vincent organization: CHU Rennes, Service de Cardiologie et Maladies Vasculaires, Rennes, F-35000, France – sequence: 3 givenname: Edouard surname: Colette fullname: Colette, Edouard organization: CHU Rennes, Service de Cardiologie et Maladies Vasculaires, Rennes, F-35000, France – sequence: 4 givenname: Nathalie surname: Behar fullname: Behar, Nathalie organization: CHU Rennes, Service de Cardiologie et Maladies Vasculaires, Rennes, F-35000, France – sequence: 5 givenname: Dominique surname: Pavin fullname: Pavin, Dominique organization: CHU Rennes, Service de Cardiologie et Maladies Vasculaires, Rennes, F-35000, France – sequence: 6 givenname: Christophe surname: Leclercq fullname: Leclercq, Christophe organization: CHU Rennes, Service de Cardiologie et Maladies Vasculaires, Rennes, F-35000, France – sequence: 7 givenname: Jean-Claude surname: Daubert fullname: Daubert, Jean-Claude organization: CHU Rennes, Service de Cardiologie et Maladies Vasculaires, Rennes, F-35000, France – sequence: 8 givenname: Philippe surname: Mabo fullname: Mabo, Philippe organization: CHU Rennes, Service de Cardiologie et Maladies Vasculaires, Rennes, F-35000, France |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27502864$$D View this record in MEDLINE/PubMed https://univ-rennes.hal.science/hal-01372358$$DView record in HAL |
BookMark | eNqNkU9v1DAQxS1URLeFD8AFReICh4QZx7En9LRa_hRpJS5wtryOTR1l4-IkK_Ht8e6WHjggTh57fvP0xu-KXYxxdIy9RKgQUL7rK3PXVzyXFTQVoHjCVgitKqUS4oKtAICXpKC-ZFfT1Oer5CSfsUuuGsiVWLHNB-fDGMYfRdY-mOGwDCYVZk7BDIUPuxSGwcwhju-LdfFzcdNc-JgKm6nggz21nrOn3gyTe_FwXrPvnz5-29yW26-fv2zW29KKFuey5h0o0TqCzqoOnRXYcQLpG2F2isgTAd-RJJS8Q-kdcjTKe6wVtFS7-pq9PevemUHfp7A36ZeOJujb9VYf3yCjvG7ogJl9c2bvUzzZ1vswWZeXGV1cJo2ESG2jlPgfFJqmJaKMvv4L7eOSxrz0iRK8rUlmCs-UTXGakvOPZhH0MTjd6xycPganocm2jyZePSgvu73rHif-JJWBmzPg8g8fgkt6ssGN1nUhOTvrLoZ_yP8G5dam5g |
CODEN | AHJOA2 |
CitedBy_id | crossref_primary_10_1111_pace_13765 crossref_primary_10_1016_j_ijcard_2019_01_002 crossref_primary_10_1111_bcpt_13517 crossref_primary_10_1093_eurjcn_zvae007 crossref_primary_10_1097_HCO_0000000000000365 crossref_primary_10_1016_j_ihj_2020_11_152 crossref_primary_10_1080_13696998_2019_1672698 crossref_primary_10_1097_01_NPR_0000526766_99089_4e crossref_primary_10_1161_JAHA_120_016380 crossref_primary_10_1161_JAHA_117_007603 crossref_primary_10_1007_s12325_022_02368_y crossref_primary_10_1007_s11739_017_1724_7 crossref_primary_10_4103_0028_3886_271256 crossref_primary_10_1111_pace_13368 |
Cites_doi | 10.1016/j.ijcard.2009.06.051 10.1093/eurheartj/ehu305 10.1056/NEJM199507063330103 10.1007/s11239-011-0621-6 10.1161/CIR.0000000000000031 10.1093/eurheartj/ehs109 10.1093/europace/eus305 10.1161/01.CIR.89.2.635 10.7326/0003-4819-146-12-200706190-00007 10.1093/europace/eut373 10.1161/CIRCULATIONAHA.114.014807 10.3109/08941939.2011.616256 10.1093/ejcts/ezt545 10.1093/eurheartj/ehv163 10.1161/CIRCULATIONAHA.107.750000 10.1093/eurheartj/ehu352 10.1016/0003-4975(95)00887-X 10.1056/NEJMoa1310907 10.1093/europace/euu178 10.1016/j.jtcvs.2011.02.011 10.2147/CLEP.S47385 10.1056/NEJMoa1007432 10.1001/jama.1994.03510350050036 10.1378/chest.11-2305 10.1093/europace/euv288 10.1016/S0140-6736(14)61106-5 10.1016/j.jacc.2014.03.022 10.1161/CIRCULATIONAHA.108.190748 10.1056/NEJMoa0905561 10.1161/CIRCULATIONAHA.113.004742 10.1016/S0002-8703(98)70231-5 10.1056/NEJMoa1009638 10.1160/TH16-01-0007 10.1161/JAHA.115.002322 10.1093/europace/euv309 |
ContentType | Journal Article |
Copyright | 2016 Elsevier Inc. Copyright © 2016 Elsevier Inc. All rights reserved. Copyright Elsevier Limited Aug 01, 2016 Distributed under a Creative Commons Attribution 4.0 International License |
Copyright_xml | – notice: 2016 Elsevier Inc. – notice: Copyright © 2016 Elsevier Inc. All rights reserved. – notice: Copyright Elsevier Limited Aug 01, 2016 – notice: Distributed under a Creative Commons Attribution 4.0 International License |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7QO 7RV 7TS 7X7 7XB 88C 88E 8AO 8C1 8FD 8FI 8FJ 8FK 8G5 ABUWG AFKRA AN0 AZQEC BENPR CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ GUQSH K9. KB0 M0S M0T M1P M2O MBDVC NAPCQ P64 PQEST PQQKQ PQUKI PRINS Q9U 7X8 1XC VOOES |
DOI | 10.1016/j.ahj.2016.05.014 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Biotechnology Research Abstracts ProQuest Nursing and Allied Health Journals Physical Education Index ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection ProQuest Public Health Database Technology Research Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni Edition) ProQuest Central British Nursing Database ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) ProQuest Healthcare Administration Database Medical Database Proquest Research Library Research Library (Corporate) Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Research Library Prep ProQuest Central Student Technology Research Database ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College Research Library (Alumni Edition) ProQuest Pharma Collection ProQuest Central China Physical Education Index ProQuest Central Health Research Premium Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Research Library ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest Central Basic ProQuest One Academic Eastern Edition British Nursing Index with Full Text ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE Research Library Prep Engineering Research Database MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1097-6744 |
EndPage | 167 |
ExternalDocumentID | oai_HAL_hal_01372358v1 4143016001 10_1016_j_ahj_2016_05_014 27502864 S0002870316300849 |
Genre | Journal Article Review |
GroupedDBID | --- --K --M .1- .55 .FO .GJ .XZ .~1 0R~ 1B1 1CY 1P~ 1RT 1~. 1~5 23M 354 3O- 3V. 4.4 41~ 457 4G. 53G 5GY 5RE 5VS 6J9 7-5 71M 7RV 7X7 88E 8AO 8C1 8F7 8FI 8FJ 8G5 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AAWTL AAXUO AAYOK ABBQC ABFNM ABFRF ABJNI ABLJU ABLVK ABMAC ABMZM ABOCM ABPPZ ABUWG ABXDB ABYKQ ACDAQ ACGFO ACGFS ACIWK ACPRK ACRLP ADBBV ADEZE ADFRT ADMUD AEBSH AEFWE AEKER AENEX AEVXI AFCTW AFFNX AFKRA AFKWA AFRAH AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AHMBA AHPSJ AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ AN0 ANZVX AQUVI ASPBG AVWKF AXJTR AZFZN AZQEC BENPR BKEYQ BKOJK BLXMC BNPGV BNQBC BPHCQ BVXVI C45 CAG CCPQU COF CS3 DWQXO EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HEB HMCUK HMK HMO HVGLF HZ~ IH2 IHE J1W J5H K-O KOM L7B LCYCR M0T M1P M29 M2O M41 MO0 N4W N9A NAPCQ O-L O9- OA. OAUVE OBH OHH OHT OL~ OVD OZT P-8 P-9 P2P PC. PQQKQ PROAC PSQYO Q38 R2- RIG ROL RPZ SAE SDF SDG SDP SEL SES SEW SPCBC SSH SSZ T5K TEORI UGJ UHS UKHRP UKR UV1 WH7 WOW WUQ X7M XCE YOC YYM YYP Z5R ZA5 ZGI ZXP ZY1 ~G- AAXKI AFJKZ AKRWK CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QO 7TS 7XB 8FD 8FK FR3 K9. MBDVC P64 PQEST PQUKI PRINS Q9U 7X8 1XC VOOES |
ID | FETCH-LOGICAL-c491t-32d0749e80dc7d1ec41d2806f54ab788f8802b868162d16fe121a7ff1370983e3 |
IEDL.DBID | .~1 |
ISSN | 0002-8703 |
IngestDate | Fri Sep 06 12:52:46 EDT 2024 Thu Aug 15 22:39:04 EDT 2024 Fri Aug 16 22:41:29 EDT 2024 Fri Sep 13 09:22:59 EDT 2024 Thu Sep 26 19:19:46 EDT 2024 Sat Sep 28 08:48:01 EDT 2024 Fri Feb 23 02:29:40 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Language | English |
License | Copyright © 2016 Elsevier Inc. All rights reserved. Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c491t-32d0749e80dc7d1ec41d2806f54ab788f8802b868162d16fe121a7ff1370983e3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 ObjectType-Article-1 ObjectType-Feature-2 |
ORCID | 0000-0002-4399-5568 |
OpenAccessLink | https://univ-rennes.hal.science/hal-01372358 |
PMID | 27502864 |
PQID | 1810429386 |
PQPubID | 2031075 |
PageCount | 7 |
ParticipantIDs | hal_primary_oai_HAL_hal_01372358v1 proquest_miscellaneous_1811895774 proquest_miscellaneous_1810559888 proquest_journals_1810429386 crossref_primary_10_1016_j_ahj_2016_05_014 pubmed_primary_27502864 elsevier_sciencedirect_doi_10_1016_j_ahj_2016_05_014 |
PublicationCentury | 2000 |
PublicationDate | August 2016 2016-08-00 20160801 2016-08 |
PublicationDateYYYYMMDD | 2016-08-01 |
PublicationDate_xml | – month: 08 year: 2016 text: August 2016 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Philadelphia |
PublicationTitle | The American heart journal |
PublicationTitleAlternate | Am Heart J |
PublicationYear | 2016 |
Publisher | Elsevier Inc Elsevier Limited Elsevier |
Publisher_xml | – name: Elsevier Inc – name: Elsevier Limited – name: Elsevier |
References | Jaffer, Stafford, Fredenburgh (bb0175) 2015; 4 Vahanian, Alfieri, Andreotti (bb0130) 2012; 33 Whitlock, Sun, Fremes (bb0135) 2012; 141 Molteni, Polo Friz, Primitz (bb0065) 2014; 16 Cannegieter, Rosendaal, Wintzen (bb0110) 1995; 333 Philippart, Brunet-Bernard, Clementy (bb0075) 2015; 36 Camm, Lip, De Caterina (bb0035) 2012; 14 Heidbuchel, Verhamme, Alings (bb0160) 2015; 17 Giugliano, Ruff, Braunwald (bb0025) 2013; 369 Connolly, Eikelboom, Joyner (bb0015) 2011; 364 Benjamin, Levy, Vaziri (bb0050) 1994; 271 Lip, Laroche, Dan (bb0045) 2014; 16 Philippart, Brunet-Bernard, Clementy (bb0140) 2016; 115 Bonow, Carabello, Chatterjee (bb0120) 2008; 118 Nakagami, Yamamoto, Ikeda (bb0085) 1998; 136 Nishimura, Otto, Bonow (bb0125) 2014; 129 Connolly, Pogue, Eikelboom (bb0190) 2008; 118 Hart, Pearce, Aguilar (bb0010) 2007; 146 Blackshear, Odell (bb0070) 1996; 61 Zoni-Berisso, Lercari, Carazza, Domenicucci (bb0005) 2014; 6 De Caterina, Camm (bb0200) 2014; 35 Avezum, Lopes, Schulte (bb0095) 2015; 132 bb0150 Kaeberich, Reindl, Raaz (bb0180) 2011; 32 . Patel, Mahaffey, Garg (bb0030) 2011; 365 Breithardt, Baumgartner, Berkowitz (bb0090) 2014; 35 McKellar, Abel, Camp (bb0165) 2011; 141 De Caterina, Camm (bb0195) 2016; 18 January, Wann, Alpert (bb0040) 2014; 64 Cannegieter, Rosendaal, Briet (bb0105) 1994; 89 Connolly, Ezekowitz, Yusuf (bb0020) 2009; 361 Greiten, McKellar, Rysavy, Schaff (bb0185) 2014; 45 Martins, Kaur, Hwang (bb0055) 2014; 129 Fukuda, Hirai, Ohara (bb0080) 2011; 146 Ruff, Giugliano, Braunwald, Antman (bb0060) 2014; 384 Eikelboom, Brueckmann, Van de Werf (bb0115) 2014; 370 Schomburg, Medina, Lahti, Bianco (bb0170) 2012; 25 Connolly (10.1016/j.ahj.2016.05.014_bb0020) 2009; 361 Martins (10.1016/j.ahj.2016.05.014_bb0055) 2014; 129 Breithardt (10.1016/j.ahj.2016.05.014_bb0090) 2014; 35 10.1016/j.ahj.2016.05.014_bb0145 10.1016/j.ahj.2016.05.014_bb0100 Nishimura (10.1016/j.ahj.2016.05.014_bb0125) 2014; 129 Camm (10.1016/j.ahj.2016.05.014_bb0035) 2012; 14 Nakagami (10.1016/j.ahj.2016.05.014_bb0085) 1998; 136 Avezum (10.1016/j.ahj.2016.05.014_bb0095) 2015; 132 Cannegieter (10.1016/j.ahj.2016.05.014_bb0110) 1995; 333 Hart (10.1016/j.ahj.2016.05.014_bb0010) 2007; 146 Whitlock (10.1016/j.ahj.2016.05.014_bb0135) 2012; 141 Cannegieter (10.1016/j.ahj.2016.05.014_bb0105) 1994; 89 Connolly (10.1016/j.ahj.2016.05.014_bb0015) 2011; 364 Heidbuchel (10.1016/j.ahj.2016.05.014_bb0160) 2015; 17 Connolly (10.1016/j.ahj.2016.05.014_bb0190) 2008; 118 McKellar (10.1016/j.ahj.2016.05.014_bb0165) 2011; 141 De Caterina (10.1016/j.ahj.2016.05.014_bb0200) 2014; 35 Zoni-Berisso (10.1016/j.ahj.2016.05.014_bb0005) 2014; 6 Molteni (10.1016/j.ahj.2016.05.014_bb0065) 2014; 16 10.1016/j.ahj.2016.05.014_bb0155 10.1016/j.ahj.2016.05.014_bb0150 Blackshear (10.1016/j.ahj.2016.05.014_bb0070) 1996; 61 De Caterina (10.1016/j.ahj.2016.05.014_bb0195) 2016; 18 Patel (10.1016/j.ahj.2016.05.014_bb0030) 2011; 365 Ruff (10.1016/j.ahj.2016.05.014_bb0060) 2014; 384 Greiten (10.1016/j.ahj.2016.05.014_bb0185) 2014; 45 Benjamin (10.1016/j.ahj.2016.05.014_bb0050) 1994; 271 Fukuda (10.1016/j.ahj.2016.05.014_bb0080) 2011; 146 Bonow (10.1016/j.ahj.2016.05.014_bb0120) 2008; 118 Kaeberich (10.1016/j.ahj.2016.05.014_bb0180) 2011; 32 Jaffer (10.1016/j.ahj.2016.05.014_bb0175) 2015; 4 Giugliano (10.1016/j.ahj.2016.05.014_bb0025) 2013; 369 Vahanian (10.1016/j.ahj.2016.05.014_bb0130) 2012; 33 Lip (10.1016/j.ahj.2016.05.014_bb0045) 2014; 16 Philippart (10.1016/j.ahj.2016.05.014_bb0140) 2016; 115 January (10.1016/j.ahj.2016.05.014_bb0040) 2014; 64 Philippart (10.1016/j.ahj.2016.05.014_bb0075) 2015; 36 Eikelboom (10.1016/j.ahj.2016.05.014_bb0115) 2014; 370 Schomburg (10.1016/j.ahj.2016.05.014_bb0170) 2012; 25 |
References_xml | – volume: 36 start-page: 1822 year: 2015 end-page: 1830 ident: bb0075 article-title: Prognostic value of CHA2DS2-VASc score in patients with 'non-valvular atrial fibrillation' and valvular heart disease: the Loire Valley Atrial Fibrillation Project publication-title: Eur Heart J contributor: fullname: Clementy – volume: 17 start-page: 1467 year: 2015 end-page: 1507 ident: bb0160 article-title: Updated European Heart Rhythm Association Practical Guide on the use of non–vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation publication-title: Europace contributor: fullname: Alings – volume: 333 start-page: 11 year: 1995 end-page: 17 ident: bb0110 article-title: Optimal oral anticoagulant therapy in patients with mechanical heart valves publication-title: N Engl J Med contributor: fullname: Wintzen – volume: 18 start-page: 6 year: 2016 end-page: 11 ident: bb0195 article-title: Non–vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial publication-title: Europace contributor: fullname: Camm – volume: 61 start-page: 755 year: 1996 end-page: 759 ident: bb0070 article-title: Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation publication-title: Ann Thorac Surg contributor: fullname: Odell – volume: 132 start-page: 624 year: 2015 end-page: 632 ident: bb0095 article-title: Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial publication-title: Circulation contributor: fullname: Schulte – volume: 365 start-page: 883 year: 2011 end-page: 891 ident: bb0030 article-title: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation publication-title: N Engl J Med contributor: fullname: Garg – volume: 136 start-page: 528 year: 1998 end-page: 532 ident: bb0085 article-title: Mitral regurgitation reduces the risk of stroke in patients with nonrheumatic atrial fibrillation publication-title: Am Heart J contributor: fullname: Ikeda – volume: 35 start-page: 3328 year: 2014 end-page: 3335 ident: bb0200 article-title: What is 'valvular' atrial fibrillation? A reappraisal publication-title: Eur Heart J contributor: fullname: Camm – volume: 364 start-page: 806 year: 2011 end-page: 817 ident: bb0015 article-title: Apixaban in patients with atrial fibrillation publication-title: N Engl J Med contributor: fullname: Joyner – volume: 129 start-page: e521 year: 2014 end-page: e643 ident: bb0125 article-title: 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines publication-title: Circulation contributor: fullname: Bonow – volume: 16 start-page: 308 year: 2014 end-page: 319 ident: bb0045 article-title: A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry publication-title: Europace contributor: fullname: Dan – volume: 25 start-page: 150 year: 2012 end-page: 155 ident: bb0170 article-title: Dabigatran versus warfarin after mechanical mitral valve replacement in the swine model publication-title: J Invest Surg contributor: fullname: Bianco – volume: 64 start-page: e1 year: 2014 end-page: e76 ident: bb0040 article-title: 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society publication-title: J Am Coll Cardiol contributor: fullname: Alpert – volume: 4 year: 2015 ident: bb0175 article-title: Dabigatran is Less Effective Than Warfarin at Attenuating Mechanical Heart Valve-Induced Thrombin Generation publication-title: J Am Heart Assoc contributor: fullname: Fredenburgh – volume: 146 start-page: 197 year: 2011 end-page: 201 ident: bb0080 article-title: Relation of the severity of mitral regurgitation to thromboembolic risk in patients with atrial fibrillation publication-title: Int J Cardiol contributor: fullname: Ohara – volume: 115 start-page: 1056 year: 2016 end-page: 1063 ident: bb0140 article-title: Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project publication-title: Thromb Haemost contributor: fullname: Clementy – volume: 146 start-page: 857 year: 2007 end-page: 867 ident: bb0010 article-title: Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation publication-title: Ann Intern Med contributor: fullname: Aguilar – volume: 141 start-page: e576S year: 2012 end-page: e600S ident: bb0135 article-title: Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines publication-title: Chest contributor: fullname: Fremes – volume: 16 start-page: 1720 year: 2014 end-page: 1725 ident: bb0065 article-title: The definition of valvular and non-valvular atrial fibrillation: results of a physicians' survey publication-title: Europace contributor: fullname: Primitz – volume: 33 start-page: 2451 year: 2012 end-page: 2496 ident: bb0130 article-title: Guidelines on the management of valvular heart disease (version 2012) publication-title: Eur Heart J contributor: fullname: Andreotti – volume: 141 start-page: 1410 year: 2011 end-page: 1416 ident: bb0165 article-title: Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves publication-title: J Thorac Cardiovasc Surg contributor: fullname: Camp – volume: 89 start-page: 635 year: 1994 end-page: 641 ident: bb0105 article-title: Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses publication-title: Circulation contributor: fullname: Briet – volume: 369 start-page: 2093 year: 2013 end-page: 2104 ident: bb0025 article-title: Edoxaban versus warfarin in patients with atrial fibrillation publication-title: N Engl J Med contributor: fullname: Braunwald – volume: 370 start-page: 383 year: 2014 end-page: 384 ident: bb0115 article-title: Dabigatran in patients with mechanical heart valves publication-title: N Engl J Med contributor: fullname: Van de Werf – volume: 118 start-page: 2029 year: 2008 end-page: 2037 ident: bb0190 article-title: Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range publication-title: Circulation contributor: fullname: Eikelboom – volume: 45 start-page: 914 year: 2014 end-page: 919 ident: bb0185 article-title: Effectiveness of rivaroxaban for thromboprophylaxis of prosthetic heart valves in a porcine heterotopic valve model publication-title: Eur J Cardiothorac Surg contributor: fullname: Schaff – volume: 32 start-page: 417 year: 2011 end-page: 425 ident: bb0180 article-title: Comparison of unfractionated heparin, low-molecular-weight heparin, low-dose and high-dose rivaroxaban in preventing thrombus formation on mechanical heart valves: results of an in vitro study publication-title: J Thromb Thrombolysis contributor: fullname: Raaz – volume: 384 start-page: 25 year: 2014 end-page: 26 ident: bb0060 article-title: New oral anticoagulants in patients with atrial fibrillation - Authors'reply publication-title: Lancet contributor: fullname: Antman – volume: 271 start-page: 840 year: 1994 end-page: 844 ident: bb0050 article-title: Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study publication-title: JAMA contributor: fullname: Vaziri – volume: 35 start-page: 3377 year: 2014 end-page: 3385 ident: bb0090 article-title: Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial publication-title: Eur Heart J contributor: fullname: Berkowitz – volume: 118 start-page: e523 year: 2008 end-page: e661 ident: bb0120 article-title: 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons publication-title: Circulation contributor: fullname: Chatterjee – ident: bb0150 – volume: 6 start-page: 213 year: 2014 end-page: 220 ident: bb0005 article-title: Epidemiology of atrial fibrillation: European perspective publication-title: Clin Epidemiol contributor: fullname: Domenicucci – volume: 14 start-page: 1385 year: 2012 end-page: 1413 ident: bb0035 article-title: 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation—developed with the special contribution of the European Heart Rhythm Association publication-title: Europace contributor: fullname: De Caterina – volume: 361 start-page: 1139 year: 2009 end-page: 1151 ident: bb0020 article-title: Dabigatran versus warfarin in patients with atrial fibrillation publication-title: N Engl J Med contributor: fullname: Yusuf – volume: 129 start-page: 1472 year: 2014 end-page: 1482 ident: bb0055 article-title: Dominant frequency increase rate predicts transition from paroxysmal to long-term persistent atrial fibrillation publication-title: Circulation contributor: fullname: Hwang – volume: 146 start-page: 197 year: 2011 ident: 10.1016/j.ahj.2016.05.014_bb0080 article-title: Relation of the severity of mitral regurgitation to thromboembolic risk in patients with atrial fibrillation publication-title: Int J Cardiol doi: 10.1016/j.ijcard.2009.06.051 contributor: fullname: Fukuda – volume: 35 start-page: 3377 year: 2014 ident: 10.1016/j.ahj.2016.05.014_bb0090 article-title: Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial publication-title: Eur Heart J doi: 10.1093/eurheartj/ehu305 contributor: fullname: Breithardt – volume: 370 start-page: 383 year: 2014 ident: 10.1016/j.ahj.2016.05.014_bb0115 article-title: Dabigatran in patients with mechanical heart valves publication-title: N Engl J Med contributor: fullname: Eikelboom – ident: 10.1016/j.ahj.2016.05.014_bb0100 – volume: 333 start-page: 11 year: 1995 ident: 10.1016/j.ahj.2016.05.014_bb0110 article-title: Optimal oral anticoagulant therapy in patients with mechanical heart valves publication-title: N Engl J Med doi: 10.1056/NEJM199507063330103 contributor: fullname: Cannegieter – ident: 10.1016/j.ahj.2016.05.014_bb0150 – volume: 32 start-page: 417 year: 2011 ident: 10.1016/j.ahj.2016.05.014_bb0180 article-title: Comparison of unfractionated heparin, low-molecular-weight heparin, low-dose and high-dose rivaroxaban in preventing thrombus formation on mechanical heart valves: results of an in vitro study publication-title: J Thromb Thrombolysis doi: 10.1007/s11239-011-0621-6 contributor: fullname: Kaeberich – volume: 129 start-page: e521 year: 2014 ident: 10.1016/j.ahj.2016.05.014_bb0125 article-title: 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines publication-title: Circulation doi: 10.1161/CIR.0000000000000031 contributor: fullname: Nishimura – volume: 33 start-page: 2451 year: 2012 ident: 10.1016/j.ahj.2016.05.014_bb0130 article-title: Guidelines on the management of valvular heart disease (version 2012) publication-title: Eur Heart J doi: 10.1093/eurheartj/ehs109 contributor: fullname: Vahanian – volume: 14 start-page: 1385 year: 2012 ident: 10.1016/j.ahj.2016.05.014_bb0035 article-title: 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation—developed with the special contribution of the European Heart Rhythm Association publication-title: Europace doi: 10.1093/europace/eus305 contributor: fullname: Camm – volume: 89 start-page: 635 year: 1994 ident: 10.1016/j.ahj.2016.05.014_bb0105 article-title: Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses publication-title: Circulation doi: 10.1161/01.CIR.89.2.635 contributor: fullname: Cannegieter – volume: 146 start-page: 857 year: 2007 ident: 10.1016/j.ahj.2016.05.014_bb0010 article-title: Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation publication-title: Ann Intern Med doi: 10.7326/0003-4819-146-12-200706190-00007 contributor: fullname: Hart – volume: 16 start-page: 308 year: 2014 ident: 10.1016/j.ahj.2016.05.014_bb0045 article-title: A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry publication-title: Europace doi: 10.1093/europace/eut373 contributor: fullname: Lip – volume: 132 start-page: 624 year: 2015 ident: 10.1016/j.ahj.2016.05.014_bb0095 article-title: Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.114.014807 contributor: fullname: Avezum – volume: 25 start-page: 150 year: 2012 ident: 10.1016/j.ahj.2016.05.014_bb0170 article-title: Dabigatran versus warfarin after mechanical mitral valve replacement in the swine model publication-title: J Invest Surg doi: 10.3109/08941939.2011.616256 contributor: fullname: Schomburg – volume: 45 start-page: 914 year: 2014 ident: 10.1016/j.ahj.2016.05.014_bb0185 article-title: Effectiveness of rivaroxaban for thromboprophylaxis of prosthetic heart valves in a porcine heterotopic valve model publication-title: Eur J Cardiothorac Surg doi: 10.1093/ejcts/ezt545 contributor: fullname: Greiten – volume: 36 start-page: 1822 year: 2015 ident: 10.1016/j.ahj.2016.05.014_bb0075 article-title: Prognostic value of CHA2DS2-VASc score in patients with 'non-valvular atrial fibrillation' and valvular heart disease: the Loire Valley Atrial Fibrillation Project publication-title: Eur Heart J doi: 10.1093/eurheartj/ehv163 contributor: fullname: Philippart – volume: 118 start-page: 2029 year: 2008 ident: 10.1016/j.ahj.2016.05.014_bb0190 article-title: Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.107.750000 contributor: fullname: Connolly – volume: 35 start-page: 3328 year: 2014 ident: 10.1016/j.ahj.2016.05.014_bb0200 article-title: What is 'valvular' atrial fibrillation? A reappraisal publication-title: Eur Heart J doi: 10.1093/eurheartj/ehu352 contributor: fullname: De Caterina – volume: 61 start-page: 755 year: 1996 ident: 10.1016/j.ahj.2016.05.014_bb0070 article-title: Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation publication-title: Ann Thorac Surg doi: 10.1016/0003-4975(95)00887-X contributor: fullname: Blackshear – volume: 369 start-page: 2093 year: 2013 ident: 10.1016/j.ahj.2016.05.014_bb0025 article-title: Edoxaban versus warfarin in patients with atrial fibrillation publication-title: N Engl J Med doi: 10.1056/NEJMoa1310907 contributor: fullname: Giugliano – volume: 16 start-page: 1720 year: 2014 ident: 10.1016/j.ahj.2016.05.014_bb0065 article-title: The definition of valvular and non-valvular atrial fibrillation: results of a physicians' survey publication-title: Europace doi: 10.1093/europace/euu178 contributor: fullname: Molteni – volume: 141 start-page: 1410 year: 2011 ident: 10.1016/j.ahj.2016.05.014_bb0165 article-title: Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves publication-title: J Thorac Cardiovasc Surg doi: 10.1016/j.jtcvs.2011.02.011 contributor: fullname: McKellar – volume: 6 start-page: 213 year: 2014 ident: 10.1016/j.ahj.2016.05.014_bb0005 article-title: Epidemiology of atrial fibrillation: European perspective publication-title: Clin Epidemiol doi: 10.2147/CLEP.S47385 contributor: fullname: Zoni-Berisso – volume: 364 start-page: 806 year: 2011 ident: 10.1016/j.ahj.2016.05.014_bb0015 article-title: Apixaban in patients with atrial fibrillation publication-title: N Engl J Med doi: 10.1056/NEJMoa1007432 contributor: fullname: Connolly – volume: 271 start-page: 840 year: 1994 ident: 10.1016/j.ahj.2016.05.014_bb0050 article-title: Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study publication-title: JAMA doi: 10.1001/jama.1994.03510350050036 contributor: fullname: Benjamin – volume: 141 start-page: e576S year: 2012 ident: 10.1016/j.ahj.2016.05.014_bb0135 article-title: Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines publication-title: Chest doi: 10.1378/chest.11-2305 contributor: fullname: Whitlock – volume: 18 start-page: 6 year: 2016 ident: 10.1016/j.ahj.2016.05.014_bb0195 article-title: Non–vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial publication-title: Europace doi: 10.1093/europace/euv288 contributor: fullname: De Caterina – volume: 384 start-page: 25 year: 2014 ident: 10.1016/j.ahj.2016.05.014_bb0060 article-title: New oral anticoagulants in patients with atrial fibrillation - Authors'reply publication-title: Lancet doi: 10.1016/S0140-6736(14)61106-5 contributor: fullname: Ruff – ident: 10.1016/j.ahj.2016.05.014_bb0155 – volume: 64 start-page: e1 year: 2014 ident: 10.1016/j.ahj.2016.05.014_bb0040 article-title: 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2014.03.022 contributor: fullname: January – volume: 118 start-page: e523 year: 2008 ident: 10.1016/j.ahj.2016.05.014_bb0120 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.108.190748 contributor: fullname: Bonow – volume: 361 start-page: 1139 year: 2009 ident: 10.1016/j.ahj.2016.05.014_bb0020 article-title: Dabigatran versus warfarin in patients with atrial fibrillation publication-title: N Engl J Med doi: 10.1056/NEJMoa0905561 contributor: fullname: Connolly – volume: 129 start-page: 1472 year: 2014 ident: 10.1016/j.ahj.2016.05.014_bb0055 article-title: Dominant frequency increase rate predicts transition from paroxysmal to long-term persistent atrial fibrillation publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.113.004742 contributor: fullname: Martins – volume: 136 start-page: 528 year: 1998 ident: 10.1016/j.ahj.2016.05.014_bb0085 article-title: Mitral regurgitation reduces the risk of stroke in patients with nonrheumatic atrial fibrillation publication-title: Am Heart J doi: 10.1016/S0002-8703(98)70231-5 contributor: fullname: Nakagami – volume: 365 start-page: 883 year: 2011 ident: 10.1016/j.ahj.2016.05.014_bb0030 article-title: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation publication-title: N Engl J Med doi: 10.1056/NEJMoa1009638 contributor: fullname: Patel – volume: 115 start-page: 1056 year: 2016 ident: 10.1016/j.ahj.2016.05.014_bb0140 article-title: Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project publication-title: Thromb Haemost doi: 10.1160/TH16-01-0007 contributor: fullname: Philippart – volume: 4 year: 2015 ident: 10.1016/j.ahj.2016.05.014_bb0175 article-title: Dabigatran is Less Effective Than Warfarin at Attenuating Mechanical Heart Valve-Induced Thrombin Generation publication-title: J Am Heart Assoc doi: 10.1161/JAHA.115.002322 contributor: fullname: Jaffer – ident: 10.1016/j.ahj.2016.05.014_bb0145 – volume: 17 start-page: 1467 year: 2015 ident: 10.1016/j.ahj.2016.05.014_bb0160 article-title: Updated European Heart Rhythm Association Practical Guide on the use of non–vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation publication-title: Europace doi: 10.1093/europace/euv309 contributor: fullname: Heidbuchel |
SSID | ssj0006286 |
Score | 2.320903 |
SecondaryResourceType | review_article |
Snippet | Non–vitamin K oral anticoagulants (NOACs) are currently recommended for patients with nonvalvular atrial fibrillation since the publication of the 4 major... Non-vitamin K oral anticoagulants (NOACs) are currently recommended for patients with nonvalvular atrial fibrillation since the publication of the 4 major... |
SourceID | hal proquest crossref pubmed elsevier |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 161 |
SubjectTerms | Anticoagulants Antithrombins Asset acquisitions Atrial Fibrillation - classification Atrial Fibrillation - drug therapy Atrial Fibrillation - etiology Bioengineering Bioprosthesis Cardiac arrhythmia Cardiology and cardiovascular system Catheters Contraindications Factor Xa Inhibitors Heart Valve Diseases - complications Heart Valve Prosthesis Human health and pathology Humans Life Sciences Mitral Valve Stenosis - complications Stroke Stroke - etiology Stroke - prevention & control Studies |
SummonAdditionalLinks | – databaseName: ProQuest Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LS8QwEB50BfEivq2uEsWTULZp0zT1Iou6LOJ6UthbaPNgEfG57u93pi9P7rVN23Qyr2S-mQG4cAKlSKkkNMqloaBiQ4Wxcch5UgofyyxKKVF48ijHz-J-mk5XYNzmwhCsstWJlaK274bOyAdoiUh3JkoOipJOAcx8cP3xGVL_KIqzNs00VmGNx-hWIGdn027rRYmCsnOEkcnb-GaF9CpmL4TxknUJT_GfhVqdEVTyPz-0skejLdhsHEk2rFd-G1bc2w6sT5pQ-S7c3DpfNX9guMFHdloQ3pQVVZcO5gno_1rD4K7YkFWfYui_MoOjCD1U3dqD59Hd0804bDomhEbkfB4msUWXIHcqsiaz3BnBLYVOfSqKEje7HqU1LpVUXMaWS-94zIvMe55kUa4Sl-xDDyflDoFxjxsdK01OkTpJidwiwlUsabhyNg3gsqWS_qgLY-gWMfaikaSaSKqjVCNJAxAtHXVj2WuLrVFxL3vsHGnevZ4qYY-HD5quUaVEyvJd8AD67ZLoRv6-9R-3BHDW3UbJoXBI8ebef-oxVJ5eqaVjuMpT9JEDOKiXu5sOVcZHthJHyydwDBv0SzVosA-9-dePO0FHZl6eVjz6CzzK7U0 priority: 102 providerName: ProQuest |
Title | Defining nonvalvular atrial fibrillation: A quest for clarification |
URI | https://dx.doi.org/10.1016/j.ahj.2016.05.014 https://www.ncbi.nlm.nih.gov/pubmed/27502864 https://www.proquest.com/docview/1810429386/abstract/ https://search.proquest.com/docview/1810559888 https://search.proquest.com/docview/1811895774 https://univ-rennes.hal.science/hal-01372358 |
Volume | 178 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT8MwDLZgSIgL4k1hoIA4IZU1bZqm3MYAjdeEEJN2i_pItCEEE2wc-e3YfQxxgAOXPhK3Te0kduTPDsCRETiKlArcTJnQFZRsKMly3-U8SIX1ZeSFFCh815PdvrgehIM56NSxMASrrOb-ck4vZuuqpFVxszUejSjG1yMvXcApa5QSFMQnUBlhnz75_IZ5UOjlzARG6tqzWWC8kuETobtkmbxT_Kab5ocEkvzNAi000eUKLFcmJGuXrVyFOfOyBot3lZN8HTrnxhbbPjBc2mNH-iCkKUuK_TmYJYj_cwmAO2VtVnyKoeXKMqQi3FBRtQH9y4vHTtet9kpwMxHziRv4ORoDsVFenkU5N5ngOTlNbSiSFJe5FsepnyqpuPRzLq3hPk8ia3kQebEKTLAJDWyU2QbGLS5xcpnF5KOTFMItPJRfSuTK5KEDxzWX9LhMiaFrrNiTRpZqYqn2Qo0sdUDUfNQ_5Kpxyv7rsUPk-ez1lAO7277VVEY5Eim-94M70KxFoquR967RYiEdGyjpwMGsGscMOUKSF_M6LWkoMb1Sf9JwFYdoHTuwVYp71hzKiY_dSuz87-d2YYnuShhhExqTt6nZQ9Nmku4XfReP0SDCo-rg9UL76qbbw_PZRe_-4Qsrj_bI |
link.rule.ids | 230,315,786,790,891,4521,12083,12250,21416,24144,27957,27958,31754,31755,33301,33302,33779,33780,43345,43614,43840,45620,45714,74102,74371,74659 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT8MwDLZgSMAF8aY8A-KEVNG0aZZyQdMADdh2Amm3qG0STQjx2uP3Y_exnbZrm7apH7ETf7YBrq1ALVIq8nNlY19QsaE0N6HPeZQJF8pmEFOicK8vO-_iZRAPqgO3UQWrrNfEYqE23zmdkd-iJaK1M1Ly_ufXp65RFF2tWmiswpqI0NBQpnh7DvGgtMuZ-4uiXUc1C3xXOvwgZJcsC3eKRXZpdUgAyUXeZ2GFnrZhq3IfWavk9w6s2K9dWO9VAfI9aD9YV7R8YLitRyGaEsqUpUVvDuYI3v9Zgt_uWIsVn2LotbIcRxFmqLi1D-9Pj2_tjl_1SfBzkfCxH4UGHYHEqsDkTcNtLrihgKmLRZrhFtehjoaZkorL0HDpLA952nSOR80gUZGNDqCBk7JHwLjD7Y2ReULxOUnp2yJA3mU0XFkTe3BTU0n_lOUwdI0T-9BIUk0k1UGskaQeiJqOurLnpZ3WuFwve-wKaT57PdW_7rS6mq5RfUTK7Z1yD05rluhK60Z6LiMeXM5uo75QECT9st-TcgwVpVdq6Riukhg9Yw8OS3bPpkP18FGsxPHyCVzARuet19Xd5_7rCWzS75WwwVNojP8m9gxdmXF2XsjrP5uT7Es |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bT4UwDG68JMYX4128TuOTCZHBGMMXc7ycHG8nxmji2wJsizHG69HfbwsDnzyvbMBou7ajX1uAfStwFymVhJWyaSio2FBRmTjkPCmFi2UWpZQofDOUgwdx-Zg-evzTl4dVtjqxVtTmraJ_5IdoiUh3JkoeOg-LuD3rH79_hNRBiiKtvp3GJExnQqYo4dMn58Pbu04vUxJm5wyjoLcxzhrtVTw9E85LNmU8xX9WavKJ4JL_-aK1TerPw5x3Jlmv4f4CTNjXRZi58eHyJTg9s65uAMHwkI8i9UOYU1bUnTqYI7D_SwOFO2I9Vr-KoQ_LKpxFCKJ6aBke-uf3p4PQd00IK5HzUZjEBt2C3KrIVJnhthLcUPjUpaIo8cDrcMfGpZKKy9hw6SyPeZE5x5MsylVikxWYwkXZNWDc4WHHyCqnaJ2kZG4RISdLmq6sSQM4aKmk35viGLpFjT1rJKkmkuoo1UjSAERLR-2te2O1NSrvcbftIc27x1M17EHvWtM1qpZImb4_PIDNliXa78Ev_ScxAex2w7h7KCRSvNq372YOlahXauwcrvIU_eQAVht2d8uh6vgoVmJ9_AJ2YAaFVV9fDK82YJa-rsEQbsLU6PPbbqFfMyq3vcD-AlqJ8iM |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Defining+nonvalvular+atrial+fibrillation%3A+A+quest+for+clarification&rft.jtitle=The+American+heart+journal&rft.au=Martins%2C+R.P.&rft.au=Galand%2C+V.&rft.au=Colette%2C+E.&rft.au=Behar%2C+N.&rft.date=2016-08-01&rft.pub=Elsevier&rft.issn=0002-8703&rft.eissn=1097-6744&rft.volume=178&rft.spage=161&rft.epage=167&rft_id=info:doi/10.1016%2Fj.ahj.2016.05.014&rft_id=info%3Apmid%2F27502864&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=oai_HAL_hal_01372358v1 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0002-8703&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0002-8703&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0002-8703&client=summon |